Clearance of Inflammatory Cytokines in Patients With Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMIC®2 Filter
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Renal Failure
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Removal of inflammatory mediators
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.
The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.
Detailed Description
In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis
- •clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary
Exclusion Criteria
- •lack of consent
- •pre-existing dialysis dependent renal failure
- •life expectancy \<24 hours
- •patients with haemoglobin \<7g/dL (unless transfused for clinical reasons)
- •need for extracorporeal membrane oxygenation (ECMO)
Outcomes
Primary Outcomes
Removal of inflammatory mediators
Time Frame: 48 hours
Clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor
Secondary Outcomes
- Adsorption of inflammatory mediators(48 hours)